Overview

Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the investigators can predict the sensitivity or resistance of colon cancer to the two available first line chemotherapy agents.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab
Capecitabine
Irinotecan
Oxaliplatin